Interclade neutralization and enhancement of human immunodeficiency virus type 1 identified by an assay using HeLa cells expressing both CD4 receptor and CXCR4/CCR5 coreceptors

被引：21

作者：

Barin, F

Brunet, S

Brand, D

Moog, C

Peyre, R

Damond, F

Charneau, P

Barre-Sinoussi, F

机构：

[1] Univ Tours, Virol Lab, EA 3250, Tours, France

[2] INSERM, U544, Inst Virol, Strasbourg, France

[3] Hop Bichat, Virol Lab, F-75877 Paris, France

[4] Inst Pasteur, Unite Oncol Virale, F-75724 Paris, France

[5] Inst Pasteur, Unite Biol Retrovirus, Paris, France

来源：

JOURNAL OF INFECTIOUS DISEASES | 2004年 / 189卷 / 02期

关键词：

D O I：

10.1086/380099

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report on the development and evaluation of a human immunodeficiency virus (HIV) neutralization assay that uses P4P cells, which are CD4(+)CXCR4(+)CCR5(+) HeLa cells that carry the lacZ gene under the control of the HIV-1 long terminal repeat. The results of the present study suggest that the P4P assay can be used for the extensive study of both neutralizing and enhancing activity in serum samples from HIV-1-infected patients and from vaccinated individuals.

引用

收藏

页码：322 / 327

页数：6

相关论文

共 15 条

[1] HIV-1 REVERSE TRANSCRIPTION - A TERMINATION STEP AT THE CENTER OF THE GENOME [J].

CHARNEAU, P ;

MIRAMBEAU, G ;

ROUX, P ;

PAULOUS, S ;

BUC, H ;

CLAVEL, F .

JOURNAL OF MOLECULAR BIOLOGY, 1994, 241 (05) :651-662

[2] AIDS - Diversity considerations in HIV-1 vaccine selection [J].

Gaschen, B ;

Taylor, J ;

Yusim, K ;

Foley, B ;

Gao, F ;

Lang, D ;

Novitsky, V ;

Haynes, B ;

Hahn, BH ;

Bhattacharya, T ;

Korber, B .

SCIENCE, 2002, 296 (5577) :2354-2360

[3] Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement [J].

Kostrikis, LG ;

Cao, YZ ;

Ngai, H ;

Moore, JP ;

Ho, DD .

JOURNAL OF VIROLOGY, 1996, 70 (01) :445-458

[4] Neutralization titres of HIV-1-specific monoclonal antibodies vary according to the batch of primary human peripheral blood lymphocytes, but do not vary coordinately [J].

McLain, L ;

Armstrong, SJ ;

Dimmock, NJ .

JOURNAL OF VIROLOGICAL METHODS, 1997, 67 (01) :69-76

[5]

Montefiori David C., 1999, AIDS Research and Human Retroviruses, V15, P689, DOI 10.1089/088922299310773

[6] Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals [J].

Moog, C ;

Fleury, HJA ;

Pellegrin, I ;

Kirn, A ;

Aubertin, AM .

JOURNAL OF VIROLOGY, 1997, 71 (05) :3734-3741

[7] Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development [J].

Moore, JP ;

Parren, PWHI ;

Burton, DR .

JOURNAL OF VIROLOGY, 2001, 75 (13) :5721-5729

[8] Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies [J].

Nishimura, Y ;

Igarashi, T ;

Haigwood, N ;

Sadjadpour, R ;

Plishka, RJ ;

Buckler-White, A ;

Shibata, R ;

Martin, MA .

JOURNAL OF VIROLOGY, 2002, 76 (05) :2123-2130

[9] Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro [J].

Parren, PWHI ;

Marx, PA ;

Hessell, AJ ;

Luckay, A ;

Harouse, J ;

Cheng-Mayer, C ;

Moore, JP ;

Burton, DR .

JOURNAL OF VIROLOGY, 2001, 75 (17) :8340-8347

[10]

REED L. J., 1938, AMER JOUR HYG, V27, P493